Conceptual foundations of acetylcarnitine supplementation in neuropsychiatric long COVID syndrome: a narrative review.
Helbing, Dario Lucas, Dommaschk, Eva-Maria, Danyeli, Lena Vera et al. · European archives of psychiatry and clinical neuroscience · 2024 · DOI
Quick Summary
This review examines whether a natural supplement called acetylcarnitine might help treat long COVID symptoms like fatigue, brain fog, and depression. Acetylcarnitine is a substance your body normally makes that helps cells produce energy. The authors looked at research showing this supplement has helped some people with similar illnesses like ME/CFS and depression, and they propose studying whether it could help long COVID patients too.
Why It Matters
This review is important because it identifies potential shared biological mechanisms between long COVID and ME/CFS—particularly mitochondrial dysfunction and energy metabolism—and proposes a specific, testable intervention. For ME/CFS patients, this work validates the overlap between these conditions and suggests that treatments showing promise in ME/CFS warrant investigation in long COVID populations.
Observed Findings
Acetylcarnitine has shown clinical efficacy in treating fatigue, depression, and cognitive impairment in ME/CFS and major depressive disorder in prior research
Acylcarnitines function as regulators of mitochondrial function and markers of cellular energy metabolism
Neuropsychiatric symptoms are the most common symptom complex in long COVID
Acetylcarnitine metabolism appears altered in neuropsychiatric and fatigue-associated disorders
Long COVID shares key clinical features with ME/CFS including fatigue, cognitive dysfunction, and depression
Inferred Conclusions
Acetylcarnitine represents a promising therapeutic candidate for long COVID based on its documented efficacy in clinically similar conditions
Shared molecular mechanisms involving mitochondrial dysfunction and energy metabolism may underlie both long COVID and ME/CFS
Future research should investigate acetylcarnitine supplementation as a treatment option for neuropsychiatric long COVID through prospective clinical trials
Treatment strategies developed for ME/CFS may be applicable to long COVID due to substantial clinical and mechanistic overlap
Remaining Questions
Does acetylcarnitine supplementation specifically improve neuropsychiatric symptoms in long COVID compared to placebo in a randomized controlled trial?
What This Study Does Not Prove
This review does not prove that acetylcarnitine is an effective treatment for long COVID or ME/CFS; it synthesizes existing evidence and proposes a rationale for future studies. It does not establish causation between acetylcarnitine deficiency and symptom development, nor does it provide clinical trial data demonstrating safety and efficacy in these populations. The similarity of symptoms across long COVID, ME/CFS, and depression does not confirm they share identical underlying mechanisms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →